Alcohol addiction Therapeutic Pipeline Market Review, H2 2017

Alcohol addiction Therapeutics Development and Professional Review Analysis 2017


Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.




Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 10, 3, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.


Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



– The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)


Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Content: Key Points

List of Tables

List of Figures


Alcohol Addiction – Overview

Alcohol Addiction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcohol Addiction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcohol Addiction – Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Arbor Pharmaceuticals LLC

AstraZeneca Plc

BioCorRx Inc

Bionex Pharmaceuticals LLC

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Company

Ethypharm SA

H. Lundbeck A/S

Heptares Therapeutics Ltd

Indivior Plc

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Montisera Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Pfizer Inc

Silence Therapeutics Plc

SK Biopharmaceuticals Co Ltd

Tonix Pharmaceuticals Holding Corp





For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check:


For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check:

Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India